Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

J Crohns Colitis. 2014 Nov;8(11):1548-50. doi: 10.1016/j.crohns.2014.06.007. Epub 2014 Jul 6.


Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies.

Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.

Keywords: Biosimilar; ECCO; Inflammatory bowel disease; Monoclonal.

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Attitude of Health Personnel*
  • Biosimilar Pharmaceuticals / therapeutic use*
  • Colitis, Ulcerative / drug therapy*
  • Crohn Disease / drug therapy*
  • Drug Approval
  • Drug Substitution
  • Europe
  • Gastroenterology
  • Health Care Surveys
  • Health Knowledge, Attitudes, Practice*
  • Humans
  • Infliximab


  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • Infliximab